New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
April 26, 2017 – Inspirion Delivery Sciences announced the FDA approval of RoxyBond (oxycodone) for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
Download PDF
Return to publications
